387 related articles for article (PubMed ID: 17525183)
1. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.
Bock F; Onderka J; Dietrich T; Bachmann B; Kruse FE; Paschke M; Zahn G; Cursiefen C
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2545-52. PubMed ID: 17525183
[TBL] [Abstract][Full Text] [Related]
2. Topical Ranibizumab inhibits inflammatory corneal hem- and lymphangiogenesis.
Bucher F; Parthasarathy A; Bergua A; Onderka J; Regenfuss B; Cursiefen C; Bock F
Acta Ophthalmol; 2014 Mar; 92(2):143-8. PubMed ID: 22994268
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation.
Hos D; Bock F; Dietrich T; Onderka J; Kruse FE; Thierauch KH; Cursiefen C
Invest Ophthalmol Vis Sci; 2008 May; 49(5):1836-42. PubMed ID: 18436817
[TBL] [Abstract][Full Text] [Related]
4. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
Chen WL; Lin CT; Lin NT; Tu IH; Li JW; Chow LP; Liu KR; Hu FR
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib inhibits inflammatory corneal lymphangiogenesis.
Detry B; Blacher S; Erpicum C; Paupert J; Maertens L; Maillard C; Munaut C; Sounni NE; Lambert V; Foidart JM; Rakic JM; Cataldo D; Noël A
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3082-93. PubMed ID: 23580490
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
Kim TI; Kim SW; Kim S; Kim T; Kim EK
Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
[TBL] [Abstract][Full Text] [Related]
7. Doxycycline enhances the inhibitory effects of bevacizumab on corneal neovascularization and prevents its side effects.
Su W; Li Z; Li Y; Lin M; Yao L; Liu Y; He Z; Wu C; Liang D
Invest Ophthalmol Vis Sci; 2011 Nov; 52(12):9108-15. PubMed ID: 22039247
[TBL] [Abstract][Full Text] [Related]
8. Transient postoperative vascular endothelial growth factor (VEGF)-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation.
Bachmann BO; Luetjen-Drecoll E; Bock F; Wiegand SJ; Hos D; Dana R; Kruse FE; Cursiefen C
Br J Ophthalmol; 2009 Aug; 93(8):1075-80. PubMed ID: 19224901
[TBL] [Abstract][Full Text] [Related]
9. Interaction between bevacizumab and murine VEGF-A: a reassessment.
Yu L; Wu X; Cheng Z; Lee CV; LeCouter J; Campa C; Fuh G; Lowman H; Ferrara N
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):522-7. PubMed ID: 18234994
[TBL] [Abstract][Full Text] [Related]
10. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation.
Bachmann BO; Bock F; Wiegand SJ; Maruyama K; Dana MR; Kruse FE; Luetjen-Drecoll E; Cursiefen C
Arch Ophthalmol; 2008 Jan; 126(1):71-7. PubMed ID: 18195221
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival.
Cursiefen C; Cao J; Chen L; Liu Y; Maruyama K; Jackson D; Kruse FE; Wiegand SJ; Dana MR; Streilein JW
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2666-73. PubMed ID: 15277490
[TBL] [Abstract][Full Text] [Related]
12. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.
Yoeruek E; Ziemssen F; Henke-Fahle S; Tatar O; Tura A; Grisanti S; Bartz-Schmidt KU; Szurman P;
Acta Ophthalmol; 2008 May; 86(3):322-8. PubMed ID: 17995975
[TBL] [Abstract][Full Text] [Related]
13. Safety profile of topical VEGF neutralization at the cornea.
Bock F; Onderka J; Rummelt C; Dietrich T; Bachmann B; Kruse FE; Schlötzer-Schrehardt U; Cursiefen C
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2095-102. PubMed ID: 19151400
[TBL] [Abstract][Full Text] [Related]
14. The effect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits.
Kang S; Chung SK
Cornea; 2010 Feb; 29(2):192-6. PubMed ID: 20098156
[TBL] [Abstract][Full Text] [Related]
15. Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts.
Bock F; Onderka J; Hos D; Horn F; Martus P; Cursiefen C
Exp Eye Res; 2008 Nov; 87(5):462-70. PubMed ID: 18789928
[TBL] [Abstract][Full Text] [Related]
16. Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids.
Hos D; Saban DR; Bock F; Regenfuss B; Onderka J; Masli S; Cursiefen C
Arch Ophthalmol; 2011 Apr; 129(4):445-52. PubMed ID: 21482870
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen kringle 5 inhibits alkali-burn-induced corneal neovascularization.
Zhang Z; Ma JX; Gao G; Li C; Luo L; Zhang M; Yang W; Jiang A; Kuang W; Xu L; Chen J; Liu Z
Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4062-71. PubMed ID: 16249481
[TBL] [Abstract][Full Text] [Related]
18. Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis.
Ricci AG; Olivares CN; Bilotas MA; Meresman GF; Barañao RI
Reprod Sci; 2011 Jul; 18(7):614-22. PubMed ID: 21266664
[TBL] [Abstract][Full Text] [Related]
19. The effect of subconjunctival suramin on corneal neovascularization in rabbits.
Lee HS; Chung SK
Cornea; 2010 Jan; 29(1):86-92. PubMed ID: 19907290
[TBL] [Abstract][Full Text] [Related]
20. Blockade of insulin receptor substrate-1 inhibits corneal lymphangiogenesis.
Hos D; Regenfuss B; Bock F; Onderka J; Cursiefen C
Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5778-85. PubMed ID: 21666240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
